Clinical trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Divarasib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-20

PhasePHASE1 / PHASE2

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

DivarasibDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

CarboplatinDRUG · verified · RxNorm: carboplatin

CisplatinDRUG · verified · RxNorm: cisplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

SeoulSouth Korea4 New YorkNew York, United States2 MadridSpain2 TokyoJapan2 MelbourneVictoria, Australia2 HoustonTexas, United States1 TorontoOntario, Canada1 BarcelonaSpain1 LondonUnited Kingdom1 MontrealQuebec, Canada1 TaipeiTaiwan1 New HavenConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05789082 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.